Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study

Objective: to compare the efficacy and tolerability of second‑line chemotherapy with original bevacizumab (Avastin) and biosimilar bevacizumab produced by “Biocad” (Avegra) in patients with metastatic colon cancer.Materials and methods. This retrospective observational study included patients with metastatic colon cancer treated in 9 clinics in the Russian Federation. Inclusion criteria were as follows: metastatic or locally advanced colon cancer and second‑line therapy with bevacizumab (Avastin or Avegra). The primary outcome measure was overall survival (OS). Secondary outcome measures included progression‑free survival (PFS), disease control rate (DCR), and incidence of adverse events associated with antiangiogenic therapy.Results. We identified 209 patients with metastatic colon cancer who received second‑line therapy with biosimilar bevacizumab (n = 37; 17.7 %) or original bevacizumab (n = 90; 43 %) or no targeted therapy (n = 82; 39.3 %) between 2014 and 2018. Patients in these three groups were matched for their main prognostic characteristics. The DCR was 59.5 % in the group of biosimilar bevacizumab, 58.9 % in the group of original bevacizumab, and 50 % in the control group (without targeted therapy). PFS was 6 months in the chemotherapy group and 8 months in the groups of bevacizumab (hazard ratio (HR) 0.77; 95 % confidence interval (CI) 0.65–0.91; p = 0.002); the difference in PFS between patients receiving biosimilar bevacizumab and original bevacizumab was insignificant (HR 1.3; 95 % CI 0.81–2.1; р = 0.3). Median OS was 16 months in the chemotherapy group, 30 months in the biosimilar bevacizumab group, and 20 months in the original bevacizumab group (HR 0.89; 95 % CI 0.72–1.1; р = 0.3). We observed a tendency to longer OS in patients receiving biosimilar bevacizumab (HR 0.44; 95 % CI 0.17–1.1; р = 0.08). Bevacizumab‑ associated toxicity was limited to arterial hypertension and was registered in 4 patients with only one patient who developed grade III hypertension.Conclusions. There was no significant difference in PFS between patients receiving biosimilar and original drug, while OS was higher in the group of biosimilar bevacizumab. Both medicines demonstrated similar toxicity. Therapy with biosimilar bevacizumab ensured lower incidence of hypertension and proteinuria compared to the original drug. An additional prospective observational study assessing the efficacy and tolerability of biosimilar bevacizumab in colon cancer patients is needed.

[1]  Юрий Сергеевич Сергеев,et al.  НЕОБХОДИМО ЛИ ДОБАВЛЯТЬ АНТИАНГИОГЕННУЮ ТЕРАПИЮ К ХИМИОТЕРАПИИ У ПАЦИЕНТОВ С МЕТАСТАТИЧЕСКИМ РАКОМ ТОЛСТОЙ КИШКИ И МУТАЦИЕЙ В ГЕНЕ BRAF? РЕЗУЛЬТАТЫ СИСТЕМАТИЧЕСКОГО ОБЗОРА И МЕТА-АНАЛИЗА , 2020 .

[2]  J. Taïeb,et al.  Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer. , 2020, Clinical colorectal cancer.

[3]  Ekaterina Ignatova,et al.  Микросателлитная нестабильность как уникальная характеристика опухолей и предиктор эффективности иммунотерапии , 2020 .

[4]  A. Tryakin,et al.  Efficacy and safety of therapy with biosimilar bevacizumab in the treatment of patients with metastatic colon cancer – a series of clinical observations , 2018, Pharmateca.

[5]  H. Jang,et al.  The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials , 2017, Oncotarget.

[6]  M. Socinski,et al.  A bioequivalence study of proposed bevacizumab biosimilar, MYL-1402O (A) vs EU-Avastin (B) and US-Avastin (C). , 2017 .

[7]  С. В. Орлов,et al.  УСПЕШНАЯ РЕГИСТРАЦИЯ ОТЕЧЕСТВЕННОГО БИОАНАЛОГА БЕВАЦИЗУМАБА – НОВЫЕ ВОЗМОЖНОСТИ ЭФФЕКТИВНОЙ ТЕРАПИИ БОЛЬНЫХ НЕПЛОСКОКЛЕТОЧНЫМ НЕМЕЛКОЛЕТОЧНЫМ РАКОМ ЛЕГКОГО , 2016 .

[8]  J. Sakamoto,et al.  FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study† , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Tjulandin,et al.  Maintenance therapy following first-line chemotherapy in metastatic colorectal cancer: toxicity and efficacy—single-institution experience , 2014, Medical Oncology.

[10]  S. Barni,et al.  FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials , 2013, Medical Oncology.

[11]  S. Kubicka,et al.  Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604) , 2008 .

[12]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.